top of page

Rusfertide Meets Primary Endpoint in Clinical Trial for PV patients

Updated: Jan 19

Protagonist Therapeutics, Inc., announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV).

Want to read more?

Subscribe to gmpnsf.org to keep reading this exclusive post.

47 views0 comments

Comments

Rated 0 out of 5 stars.
Couldn’t Load Comments
It looks like there was a technical problem. Try reconnecting or refreshing the page.
bottom of page